172 related articles for article (PubMed ID: 27993886)
1. Acquired Dysfibrinogenemia Caused by Autoantibody Inhibiting Fibrin Polymerization in a Patient with MELAS Syndrome and Bleeding Tendency.
Lee N; Kim JE; Yoo HJ; Gu J; Kim H; Chung J; Koh Y; Kim HK
Ann Clin Lab Sci; 2016 Dec; 46(6):696-700. PubMed ID: 27993886
[TBL] [Abstract][Full Text] [Related]
2. A novel mutation in the fibrinogen Aα chain (Gly13Arg, fibrinogen Nanning) causes congenital dysfibrinogenemia associated with defective peptide A release.
Yan J; Luo M; Cheng P; Liao L; Deng X; Deng D; Lin F
Int J Hematol; 2017 Apr; 105(4):506-514. PubMed ID: 27933517
[TBL] [Abstract][Full Text] [Related]
3. Autoantibody to plasma fibrinopeptide A in a patient with a severe acquired haemorrhagic syndrome.
Gris JC; Schved JF; Branger B; Aguilar-Martinez P; Vécina F; Oulès R; Sarlat C; Fourcade J
Blood Coagul Fibrinolysis; 1992 Oct; 3(5):519-29. PubMed ID: 1450318
[TBL] [Abstract][Full Text] [Related]
4. Acquired dysfibrinogenemia: monoclonal λ-type IgA binding to fibrinogen caused lower functional plasma fibrinogen level and abnormal clot formation.
Arai S; Kamijo T; Takezawa Y; Sugano M; Nakazawa H; Yanagisawa R; Uehara T; Honda T; Okumura N
Int J Hematol; 2020 Jul; 112(1):96-104. PubMed ID: 32253663
[TBL] [Abstract][Full Text] [Related]
5. Fibrinogen Guarenas I: partial characterization of a new dysfibrinogenemia with an altered rate of fibrinopeptide release and an impaired polymerization.
Lundberg UG; Rodriguez S; Marchi R; Ruiz-Saez A; Arocha-Piñango CL
Thromb Res; 1995 Apr; 78(2):95-106. PubMed ID: 7482436
[TBL] [Abstract][Full Text] [Related]
6. Dysfibrinogenemia-associated novel heterozygous mutation, Shanghai (FGA c.169_180+2 del), leads to N-terminal truncation of fibrinogen Aα chain and impairs fibrin polymerization.
Zhou J; Ding Q; Wu W; Ouyang Q; Xie Y; Wu X; Lu Y; Dai J; Liang Q; Wang H; Wang X; Hu Y
J Clin Pathol; 2017 Feb; 70(2):145-153. PubMed ID: 27555433
[TBL] [Abstract][Full Text] [Related]
7. Spontaneous reversal of acquired autoimmune dysfibrinogenemia probably due to an antiidiotypic antibody directed to an interspecies cross-reactive idiotype expressed on antifibrinogen antibodies.
Ruiz-Arguelles A
J Clin Invest; 1988 Sep; 82(3):958-63. PubMed ID: 3262127
[TBL] [Abstract][Full Text] [Related]
8. Fibrinogen Alès: a homozygous case of dysfibrinogenemia (gamma-Asp(330)-->Val) characterized by a defective fibrin polymerization site "a".
Lounes KC; Soria C; Mirshahi SS; Desvignes P; Mirshahi M; Bertrand O; Bonnet P; Koopman J; Soria J
Blood; 2000 Nov; 96(10):3473-9. PubMed ID: 11071644
[TBL] [Abstract][Full Text] [Related]
9. A naturally occurring antibody that inhibits fibrin polymerization.
Hoots WK; Carrell NA; Wagner RH; Cooper HA; McDonagh J
N Engl J Med; 1981 Apr; 304(15):857-61. PubMed ID: 7207522
[TBL] [Abstract][Full Text] [Related]
10. Acquired dysfibrinogenemia caused by monoclonal production of immunoglobulin lambda light chain.
Dear A; Brennan SO; Sheat MJ; Faed JM; George PM
Haematologica; 2007 Nov; 92(11):e111-7. PubMed ID: 18024387
[TBL] [Abstract][Full Text] [Related]
11. Idiopathic autoantibody that inhibits fibrin monomer polymerization.
Ghosh S; McEvoy P; McVerry BA
Br J Haematol; 1983 Jan; 53(1):65-72. PubMed ID: 6848127
[TBL] [Abstract][Full Text] [Related]
12. An acquired inhibitor that produced a delay of fibrinopeptide B release in an asymptomatic patient.
Llobet D; Borrell M; Vila L; Vallvé C; Felices R; Fontcuberta J
Haematologica; 2007 Feb; 92(2):e17-9. PubMed ID: 17405747
[TBL] [Abstract][Full Text] [Related]
13. Dysfibrinogenemia and lupus anticoagulant in a patient with recurrent thrombosis.
Al-Mondhiry H; Galanakis D
J Lab Clin Med; 1987 Dec; 110(6):726-33. PubMed ID: 3119749
[TBL] [Abstract][Full Text] [Related]
14. Fibrinogen Nový Jicín and Praha II: cases of hereditary Aalpha 16 Arg-->Cys and Aalpha 16 Arg-->His dysfibrinogenemia.
Kotlín R; Chytilová M; Suttnar J; Riedel T; Salaj P; Blatný J; Santrůcek J; Klener P; Dyr JE
Thromb Res; 2007; 121(1):75-84. PubMed ID: 17408725
[TBL] [Abstract][Full Text] [Related]
15. [Increased thrombin time in a patient with multiple myeloma].
Bohler A; Redondo M; Lämmle B
Ther Umsch; 1999 Sep; 56(9):491-4. PubMed ID: 10517116
[TBL] [Abstract][Full Text] [Related]
16. Dysfibrinogenemia associated with liver disease.
Palascak JE; Martinez J
J Clin Invest; 1977 Jul; 60(1):89-95. PubMed ID: 874092
[TBL] [Abstract][Full Text] [Related]
17. Fibrinogen Baltimore IV: congenital dysfibrinogenemia with delayed fibrin monomer polymerization.
Ebert RF; Bell WR
Thromb Res; 1985 Apr; 38(2):121-8. PubMed ID: 4002201
[TBL] [Abstract][Full Text] [Related]
18. A hereditary dysfibrinogenemia: fibrinogen Awaji.
Matsuo T; Okuno S; Mukaida T; Ueshima S; Okada K; Matsuo O
Haemostasis; 1987; 17(1-2):89-97. PubMed ID: 3596361
[TBL] [Abstract][Full Text] [Related]
19. Acquired coagulation inhibitor delaying fibrinopeptide release.
Marciniak E; Greenwood MF
Blood; 1979 Jan; 53(1):81-92. PubMed ID: 758215
[TBL] [Abstract][Full Text] [Related]
20. Acquired dysfibrinogenemia secondary to multiple myeloma.
Kotlín R; Sobotková A; Riedel T; Salaj P; Suttnar J; Reicheltová Z; Májek P; Khaznadar T; Dyr JE
Acta Haematol; 2008; 120(2):75-81. PubMed ID: 18841003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
